What are the prescribing guidelines for nitrofurantoin (Macrobid) in patients with reduced estimated glomerular filtration rate (eGFR)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Nitrofurantoin (Macrobid) Should Be Avoided in Patients with eGFR <30 mL/min/1.73 m²

The FDA-approved drug label contraindications must be followed: nitrofurantoin is contraindicated when eGFR is <30 mL/min/1.73 m² and should not be initiated when eGFR is 30-60 mL/min/1.73 m² unless benefits clearly outweigh risks. 1

Current FDA Labeling and Guideline Recommendations

The FDA drug label does not provide explicit eGFR-based dosing adjustments but emphasizes that nitrofurantoin requires adequate renal function for therapeutic urinary concentrations 1. The KDOQI guidelines explicitly caution against using nitrofurantoin when GFR <60 mL/min/1.73 m² due to concerns about both reduced efficacy (inadequate urinary drug concentrations) and increased toxicity risk 2.

The 2011 IDSA/ESMID guidelines for uncomplicated cystitis recommend nitrofurantoin monohydrate/macrocrystals (100 mg twice daily for 5 days) as first-line therapy but do not specifically address renal function thresholds 3. More recent 2024 guidelines for UTI management recommend nitrofurantoin as a reasonable first-line choice for uncomplicated cystitis based on efficacy and low resistance rates 4.

Evidence-Based Thresholds by Renal Function

eGFR ≥60 mL/min/1.73 m²

  • Safe and effective: Use standard dosing (100 mg twice daily for 5-7 days) 3, 4
  • Clinical cure rates remain high (>80%) for most uropathogens 5, 6
  • Nitrofurantoin remains first-line therapy at this level of function

eGFR 30-60 mL/min/1.73 m²

  • Controversial zone with conflicting evidence:

    • The original contraindication at <60 mL/min was based on 1968 pharmacokinetic data showing reduced urinary drug recovery, but these studies had significant methodological limitations and did not measure clinical outcomes 7
    • Recent observational data suggest nitrofurantoin may retain efficacy down to eGFR 30-40 mL/min for uncomplicated cystitis 7, 8, 5
    • However, clinical failure rates increase progressively as eGFR declines below 60 mL/min 5, 6, 9
  • Practical approach for eGFR 40-60 mL/min: Consider nitrofurantoin if:

    • Patient has uncomplicated cystitis (not pyelonephritis)
    • Gram-negative organism (especially E. coli) is suspected or confirmed
    • Alternative agents have resistance concerns or contraindications
    • Monitor closely for treatment failure 7, 8
  • For eGFR 30-40 mL/min: Strongly prefer alternative agents (fosfomycin, trimethoprim-sulfamethoxazole if susceptible, or fluoroquinolones) as clinical cure rates with nitrofurantoin drop significantly in this range 5, 6

eGFR <30 mL/min/1.73 m²

  • Contraindicated: Do not use 2, 1
  • Inadequate urinary concentrations for efficacy
  • Increased risk of systemic toxicity including pulmonary fibrosis with chronic use 10
  • Alternative agents must be selected based on local resistance patterns

Organism-Specific Considerations

The effectiveness of nitrofurantoin varies significantly by pathogen and renal function:

  • E. coli: Maintains ~89% susceptibility and reasonable efficacy down to eGFR 40-60 mL/min 6, 11, 12
  • K. pneumoniae: Only 15% susceptibility; avoid nitrofurantoin regardless of renal function 11
  • Gram-positive organisms: Require higher eGFR (approaching 100 mL/min) for 80% cure rates 9

Critical Safety Warnings

Pulmonary Toxicity Risk

Long-term or repeated nitrofurantoin use carries risk of irreversible pulmonary fibrosis, particularly in elderly patients and those with any degree of renal impairment 10. This risk exists even with eGFR >60 mL/min but increases with declining renal function. Patients should be counseled about respiratory symptoms (dyspnea, cough) and monitored accordingly.

Drug Interactions

  • Avoid concomitant magnesium trisilicate antacids (reduces absorption) 1
  • Uricosuric drugs (probenecid, sulfinpyrazone) increase serum levels and toxicity while decreasing urinary efficacy 1

Alternative Agents When Nitrofurantoin Is Inappropriate

For patients with eGFR <60 mL/min requiring UTI treatment:

  1. Fosfomycin 3g single dose: Effective across all levels of renal function, including eGFR <30 mL/min; particularly effective when eGFR <60 mL/min compared to nitrofurantoin 6

  2. Trimethoprim-sulfamethoxazole: Requires dose adjustment when eGFR <30 mL/min but remains an option if local resistance <20% 3, 4

  3. Fluoroquinolones (ciprofloxacin, levofloxacin): Require 50% dose reduction when eGFR <15 mL/min; reserve for complicated infections due to collateral damage concerns 3, 2

  4. Beta-lactams (cephalosporins): First-generation agents for pyelonephritis; ceftriaxone for IV therapy; various dose adjustments needed based on specific agent and eGFR 4

Summary Algorithm

For uncomplicated cystitis in women:

  • eGFR ≥60: Nitrofurantoin 100 mg BID × 5 days (first-line)
  • eGFR 40-60: Consider nitrofurantoin with close monitoring OR prefer fosfomycin 3g × 1 dose
  • eGFR 30-40: Fosfomycin 3g × 1 dose preferred; avoid nitrofurantoin
  • eGFR <30: Contraindicated; use fosfomycin or adjusted-dose alternatives based on susceptibility

For pyelonephritis or complicated UTI: Nitrofurantoin is not appropriate regardless of renal function; use systemic agents (fluoroquinolones, cephalosporins, or carbapenems based on severity and resistance patterns) 3, 4

References

Research

Kidney function and the use of nitrofurantoin to treat urinary tract infections in older women.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2015

Research

The effectiveness of nitrofurantoin, fosfomycin and trimethoprim for the treatment of cystitis in relation to renal function.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2020

Research

Updated Nitrofurantoin Recommendations in the Elderly: A Closer Look at the Evidence.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2016

Research

Long term nitrofurantoin induced interstitial lung disease: a case series and literature review.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2023

Related Questions

In a 24-year-old patient with type 1 diabetes mellitus and an estimated glomerular filtration rate of 50 mL/min/1.73 m² who has a urinary tract infection, is nitrofurantoin (Macrobid) an appropriate treatment?
Is nitrofurantoin appropriate for a 62-year-old woman with an eGFR (estimated glomerular filtration rate) of 79 mL/min/1.73 m² who has an uncomplicated urinary tract infection?
In an elderly patient with urinary frequency, sulfonamide allergy, a recent estimated glomerular filtration rate of 72 mL/min/1.73 m², and urinalysis positive for nitrite, can I prescribe nitrofurantoin (Macrobid) 100 mg orally twice daily for 7 days?
Can Macrobid (nitrofurantoin) be used to treat an uncomplicated lower urinary tract infection caused by alpha‑hemolytic streptococcus in a patient with creatinine clearance ≥30 mL/min?
Is it appropriate to give prophylactic nitrofurantoin (Macrobid) 100 mg twice daily to a patient with stage 4 chronic kidney disease (eGFR ≈ 15–29 mL/min)?
Should a patient with nonobstructive coronary artery disease continue both aspirin and clopidogrel (Plavix) if he has no bleeding problems?
Is a male-to-female transgender patient who has completed five facial laser hair‑removal sessions, still has residual terminal facial hair, and experiences dysphoric symptoms several times per day but does not meet criteria for full body‑dysmorphic disorder eligible for electrolysis authorization (RFS) given the two required criteria?
What are the brand names of naloxone?
What are the causes, clinical presentation, diagnostic work‑up, and management of salt‑wasting syndromes?
Does Multaq (dronedarone) affect serum creatinine levels?
What is guideline‑directed medical therapy (GDMT)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.